StockNews.com Initiates Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)

StockNews.com started coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research note issued to investors on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Price Performance

Shares of NASDAQ GLMD opened at $0.40 on Wednesday. Galmed Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $7.80. The stock has a market capitalization of $2.02 million, a PE ratio of -0.12 and a beta of 0.87. The business has a fifty day moving average price of $0.36 and a two-hundred day moving average price of $0.38.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.